Skip to main content
SpringerLink
Log in

Vantictumab and OMP-54F78 trials on hold to assess adverse events

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. OncoMed Pharmaceuticals. OncoMed Voluntarily Halts Enrollment and Dosing in Phase 1 Vantictumab and Fzd8-Fc Trials. Media Release : 13 Jun 2014. Available from: URL: http://www.oncomed.com

  2. OncoMed Pharmaceuticals. Vantictumab Placed on Partial Clinical Hold by FDA Following Voluntary Halt by OncoMed. Media Release : 13 Jun 2014. Available from: URL: http://www.oncomed.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vantictumab and OMP-54F78 trials on hold to assess adverse events. Reactions Weekly 1509, 2 (2014). https://doi.org/10.1007/s40278-014-1781-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-1781-x

Search

Navigation